Vimarsana
Biggest News Aggregation in the World

Page 49 - Genetics Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Genetics Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Genetics Inc Today - Breaking & Trending Today

Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2023 Earnings Call Transcript - Vimarsana News

Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2023 Earnings Call Transcript

Matthew Scalo: Okay. Good afternoon, and welcome to the Myriad Genetics' First Quarter 2023 Earnings Call. During the call, we will review the financial results we released today.

Financial Review: Lucira Health (NASDAQ:LHDXQ) and Myriad Genetics (NASDAQ:MYGN) - Vimarsana News

Financial Review: Lucira Health (NASDAQ:LHDXQ) and Myriad Genetics (NASDAQ:MYGN)

Lucira Health (NASDAQ:LHDXQ – Get Rating) and Myriad Genetics (NASDAQ:MYGN – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation. Valuation & Earnings This table compares Lucira Health and […]

Swiss National Bank Sells 113,800 Shares of Moderna, Inc. (NASDAQ:MRNA) - Vimarsana News

Swiss National Bank Sells 113,800 Shares of Moderna, Inc. (NASDAQ:MRNA)

Myriad Genetics (NASDAQ:MYGN – Get Rating) issued an update on its FY23 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of ($0.36)-($0.24) for the period, compared to the consensus estimate of ($0.33). The company issued revenue guidance of $730-$750 million, compared to the consensus revenue estimate of $733.63 million. Myriad […]

Myriad Genetics (NASDAQ:MYGN) Issues FY23 Earnings Guidance - Vimarsana News

Myriad Genetics (NASDAQ:MYGN) Issues FY23 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN – Get Rating) updated its FY23 earnings guidance on Wednesday. The company provided EPS guidance of ($0.36)-($0.24) for the period, compared to the consensus EPS estimate of ($0.33). The company issued revenue guidance of $730-$750 million, compared to the consensus revenue estimate of $733.63 million. Myriad Genetics also updated its FY 2023 […]

Myriad Genetics (NASDAQ:MYGN) Updates FY23 Earnings Guidance - Vimarsana News

Myriad Genetics (NASDAQ:MYGN) Updates FY23 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN – Get Rating) updated its FY23 earnings guidance on Wednesday. The company provided EPS guidance of ($0.36)-($0.24) for the period, compared to the consensus EPS estimate of ($0.33). The company issued revenue guidance of $730-$750 million, compared to the consensus revenue estimate of $733.63 million. Myriad Genetics also updated its FY 2023 […]

Source: wkrb13.com